- Home
- KODK vs CAPR Comparison
KODK vs CAPR Comparison
Compare KODK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KODK
- CAPR
- Stock Information
- Founded
- KODK 1880
- CAPR 2005
- Country
- KODK United States
- CAPR United States
- Employees
- KODK N/A
- CAPR N/A
- Industry
- KODK Business Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KODK Consumer Discretionary
- CAPR Health Care
- Exchange
- KODK Nasdaq
- CAPR Nasdaq
- Market Cap
- KODK 385.4M
- CAPR 332.5M
- IPO Year
- KODK N/A
- CAPR N/A
- Fundamental
- Price
- KODK $5.37
- CAPR $19.20
- Analyst Decision
- KODK
- CAPR Strong Buy
- Analyst Count
- KODK 0
- CAPR 6
- Target Price
- KODK N/A
- CAPR $35.50
- AVG Volume (30 Days)
- KODK 456.1K
- CAPR 1.9M
- Earning Date
- KODK 11-15-2024
- CAPR 11-13-2024
- Dividend Yield
- KODK N/A
- CAPR N/A
- EPS Growth
- KODK N/A
- CAPR N/A
- EPS
- KODK 0.57
- CAPR N/A
- Revenue
- KODK $1,060,000,000.00
- CAPR $27,152,218.00
- Revenue This Year
- KODK N/A
- CAPR N/A
- Revenue Next Year
- KODK N/A
- CAPR $135.53
- P/E Ratio
- KODK $9.75
- CAPR N/A
- Revenue Growth
- KODK N/A
- CAPR 187.15
- 52 Week Low
- KODK $3.33
- CAPR $2.68
- 52 Week High
- KODK $6.18
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- KODK 67.75
- CAPR 53.80
- Support Level
- KODK $4.66
- CAPR $17.50
- Resistance Level
- KODK $5.60
- CAPR $20.37
- Average True Range (ATR)
- KODK 0.20
- CAPR 1.57
- MACD
- KODK 0.08
- CAPR -0.73
- Stochastic Oscillator
- KODK 84.34
- CAPR 24.91
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. The company operates via several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.